Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

By afschroeder • October 13, 2025

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan Y, Yang L. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 Oct 13;18(1):86. doi: 10.1186/s13045-025-01736-9. PMID: 41077583.

Tags: allogeneic CAR-NKT cells, Allogeneic cell therapy, allorejection, Cedars Sinai DoM, CRISPR-Cas9 gene editing, Hematology/Oncology, HLA ablation, Mesothelin-targeting CAR (MCAR), Metastatic model, Multiple tumor targeting mechanism, Off-the-shelf, Orthotopic model, Potent antitumor activity, Publications, Triple-negative breast cancer (TNBC), tumor microenvironment (TME), Tumor-associated macrophage (TAM)

Stress Trajectory and Hypertension 2 to 7 Years After Delivery: A nuMoM2b-HHS Study

Nuckols VR, Barone Gibbs B, Brewer BC, Gaffey AE, Greaney JL, Patterson F, Greenland P, Saade GR, Grobman WA, Yee LM, Bairey Merz CN, Chung[...]

Dietary Intake of Macronutrients and Micronutrients in Women with Functional Hypothalamic Amenorrhea

Uddenberg ER, Safwan N, Castaneda R, Saadedine M, Maughan J, Hurtado Andrade MD, Faubion SS, Pisarska MD, Berga SL, Manson JE, Merz CNB, Shufelt CL.[...]

Dynamic transcriptomic remodeling in grafted human neural progenitor cells uncovers mechanisms for vision preservation in a rat model of retinitis pigmentosa

Shahin S, Bell S, Lu B, Banerjee S, Swarup V, Xu H, Chetsawang J, Ramirez S, Alfaro JS, Laperle A, Svendsen S, Svendsen CN, Wang[...]